9–10 Sept 2023
PSI
Europe/Zurich timezone

Session

Apéro / Facility Tour / Poster Session

9 Sept 2023, 16:30
WHGA/001 (PSI)

WHGA/001

PSI

Presentation materials

There are no materials yet.

  1. Jacob Brunner
    09/09/2023, 16:30
  2. Anestis Nakas
    09/09/2023, 16:30
  3. Britta WEBER (Danish Center for particle Therapy)
    09/09/2023, 16:30

    Introduction
    Radiotherapy is an effective local treatment option in patients with hepatocellular carcinoma (HCC). However, photon radiotherapy is not a widely used modality in HCC as most patients have underlying cirrhosis making the liver more sensitive to radiation induced liver disease (RILD).

    The aim of this national phase II study (NCT05203120) is to investigate feasibility and safety...

    Go to contribution page
  4. Giuliano Perotti Bernardini
    09/09/2023, 16:30
  5. Suryakant Kaushik
    09/09/2023, 16:30
  6. Luciano Rivetti
    09/09/2023, 16:30
  7. Beatrice Foglia
    09/09/2023, 16:30

    INTRODUCTION
    To monitor range uncertainties in proton therapy, dose reconstruction is desirable,
    and it has already been proposed in the literature starting from detected secondary radiation, mostly positron emitters (PE). Prompt-gammas (PG) can be alternatively used:
    emitted within nanoseconds after nuclear interactions, they can be exploited for realtime adaptation.

    MATERIAL AND...

    Go to contribution page
  8. Evangelia Choulilitsa
    09/09/2023, 16:30
  9. Zihang Qiu
    09/09/2023, 16:30
  10. Hanna Rahbek Mortensen (Danish Center for Particle Therapy)
    09/09/2023, 16:30

    The aim of the Danish randomized HERAN2 trial is to examine if heterogeneous and hypofractionated proton radiotherapy can improve survival compared with X-ray radiotherapy in patients with locally advanced NSCLC who are not candidates for standard chemoradiotherapy. Patients selected for proton therapy are treated at the Danish Center for Particle Therapy and hereby, we present our treatment...

    Go to contribution page
  11. Ivar Bengtsson (RaySearch Laboratories & KTH, Royal Institute of Technology)
    09/09/2023, 16:30

    The interplay between the beam delivery time structure and the patient motion makes 4D dose calculation (4DDC) important when treating moving tumors with IMPT. In a conventional 4DDC, each spot is assigned to its nearest phase image in a 4DCT, based on a delivery log and a breathing signal. The doses computed on the phase images are then deformed to a reference phase and accumulated. An...

    Go to contribution page
  12. Nadine Vatterodt
    09/09/2023, 16:30
  13. Andreas Smolders
    09/09/2023, 16:30
  14. Art Galapon
    09/09/2023, 16:30
  15. Xia Li
    09/09/2023, 16:30
  16. Gauthier Rotsart de Hertaing (UCLouvain)
    09/09/2023, 16:30

    In radiotherapy, forecasting the motion of a lung tumor is a fundamental task for dose delivery. Indeed, anticipating the motion saves time in the decision-making process for real-time applications and could lead to a better homogeneous dose delivery and more healthy tissues spared. Our method is trained and tested on fluoroscopic sequences generated from 4D-Computed Tomography (4DCT) scans...

    Go to contribution page
  17. Hiraku Iramina (Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University)
    09/09/2023, 16:30

    [Purpose] kV-CBCT imaging during MV beam irradiation technique has been developed on C-arm linac. The purpose of this study was to quantify the performance of the intra-irradiation imaging technique under a phase-gated condition.
    [Method] TrueBeam Developer mode was used to perform the intra-irradiation imaging. Catphan504 phantom was used. To demonstrate respiratory movement, the phantom was...

    Go to contribution page
  18. Cosimo Galeone
    09/09/2023, 16:30

    Introduction
    The estimation of dose errors is a key part of online adaptive particle therapy. Interplay distorts dose distributions leading to non-ideal tumor coverage and higher dose to healthy tissues.
    Fast forward dose calculation (FDC) is mandatory to verify the efficacy of motion mitigation strategies during treatment. We propose and validate in silico a system to reconstruct the...

    Go to contribution page
  19. Line Bjerregaard Stick (Danish Centre for Particle Therapy)
    09/09/2023, 16:30

    Background
    Proton therapy for breast cancer is usually given in free breathing (FB). With the use of deep inspiration breath-hold (DIBH) technique, the location of the heart is shifted more caudally, away from the internal mammary nodes (IMN) and, thus, the dose to the heart could potentially be reduced. The aim of this study was to compare proton therapy in FB with proton therapy in DIBH for...

    Go to contribution page
  20. Stefanie Bertschi
    09/09/2023, 16:30
Building timetable...